Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Guilford Gliadel to be priced at $6,000 to $8,000 per treatment, CEO tells analysts.

Executive Summary

GUILFORD GLIADEL WILL COST $6,000 TO $8,000 PER TREATMENT, which consists of eight polymer wafers containing the chemotherapeutic agent carmustine, Guilford CEO Craig Smith, MD, told analysts at the Alex. Brown conference in Baltimore. A Treatment IND for Gliadel is approaching 75 patients enrolled, Smith said. The company filed an NDA for Gliadel for the treatment of malignant glioma as an adjunct to brain surgery in February, and the product will be reviewed by the FDA Oncologic Drugs Advisory Committee on June 14 ("The Pink Sheet" May 13, In Brief).
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS028212

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel